These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 9149897)

  • 1. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D.
    Chow KC; Ma J; Lin LS; Chi KH; Yen SH; Liu SM; Liu WT; Chen WK; Chang TH; Chen KY
    Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):363-8. PubMed ID: 9149897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus.
    Nadala EC; Tan TM; Wong HM; Ting RC
    J Med Virol; 1996 Sep; 50(1):93-6. PubMed ID: 8890046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy.
    Shimakage M; Ikegami N; Chatani M; Yoshino K; Sato T
    Biken J; 1987 Jun; 30(2):45-51. PubMed ID: 2830879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma].
    Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J
    Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
    J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases.
    Marchini B; Dolcher MP; Sabbatini A; Klein G; Migliorini P
    J Autoimmun; 1994 Apr; 7(2):179-91. PubMed ID: 7518683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma.
    Liu MY; Chang YL; Ma J; Yang HL; Hsu MM; Chen CJ; Chen JY; Yang CS
    J Med Virol; 1997 Jul; 52(3):262-9. PubMed ID: 9210034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
    Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
    Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma.
    Liu MY; Huang YT; Sheen TS; Chen JY; Tsai CH
    J Med Virol; 2004 Aug; 73(4):574-82. PubMed ID: 15221902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma.
    Luo YL; Ou GP; Chi PD; Liang YN; Liu YH; Huang MY
    Ai Zheng; 2009 Jan; 28(1):76-8. PubMed ID: 19448423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
    Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.